Human Cytotoxic T-Cell Responses Against Epstein-Barr Virus Nuclear Antigens Demonstrated by Using Recombinant Vaccinia Viruses

Autor: Murray, R. J., Kurilla, M. G., Griffin, H. M., Brooks, J. M., Mackett, M., Arrand, J. R., Rowe, M., Burrows, S. R., Moss, D. J., Kieff, E., Rickinson, A. B.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 1990 Apr 01. 87(8), 2906-2910.

Externí odkaz: https://www.jstor.org/stable/2354067

The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

Autor: Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R., Gandhi, M. K.

Publikováno v: Clinical and Experimental Immunology

In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein-Barr virus (EBV) latency-II antigens [EBV nuclear antigen 1 (EBNA1)/latent membrane protein (LMP)1/LMP2A] are present (EBV(+) cHL) in the malignant cells and antigen presentation is intact.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5d306324c5ac26f09ae2654b9a4d028b
http://europepmc.org/articles/PMC4711160

Epstein-Barr virus as a potentiator of autoimmune diseases.

Autor: Robinson WH; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA. wrobins@stanford.edu.; VA Palo Alto Health Care System, Palo Alto, CA, USA. wrobins@stanford.edu., Younis S; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.; VA Palo Alto Health Care System, Palo Alto, CA, USA., Love ZZ; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.; VA Palo Alto Health Care System, Palo Alto, CA, USA., Steinman L; Department of Neurology and Neurological Sciences and Paediatrics, Stanford University School of Medicine, Stanford, CA, USA., Lanz TV; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.; Institute for Immunity Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.

Publikováno v: Nature reviews. Rheumatology [Nat Rev Rheumatol] 2024 Nov; Vol. 20 (11), pp. 729-740. Date of Electronic Publication: 2024 Oct 10.

Phosphorescent Pd^II–Pd^II Emitter‐Based Red OLEDs with an EQEmax of 20.52%.

Autor: Qiao, Lige¹ (AUTHOR), Kong, Xiangjun¹ (AUTHOR), Li, Kechun¹ (AUTHOR), Yuan, Lequn¹ (AUTHOR), Shen, Yunjun¹ (AUTHOR), Zhang, Yuzhen¹ (AUTHOR) zhangyuzhen@gxmzu.edu.cn, Zhou, Liang² (AUTHOR) zhoul@ciac.ac.cn

Publikováno v: Advanced Science. 9/18/2024, Vol. 11 Issue 35, p1-7. 7p.

EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2

Autor: Rajiv Khanna, Burrows, S. R., Suhrbier, A., Jacob, C. A., Griffin, H., Misko, I. S., Sculley, T. B., Rowe, M., Rickinson, A. B., Moss, D. J.

Publikováno v: Scopus-Elsevier

The pathogenesis of EBV+ Burkitt's lymphoma (BL) suggests evasion of the CTL response against EBV. Two important features of this tumor have been previously suggested to explain this immune evasion, (a) absence/low expression of cellular adhesion mol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9c1a1086cd5952b7f3d37327119292e
https://doi.org/10.4049/jimmunol.150.11.5154